Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Company Deals

Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy

Fineline Cube Jan 15, 2026
Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Fineline Cube Jan 15, 2026
Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Fineline Cube Jan 15, 2026
Company Drug

Hengrui Pharmaceuticals Receives New Approval for Remimazolam Tosylate

Fineline Cube Dec 26, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced one new supplementary approval for its gamma-aminobutyric...

Company Deals

Neurophth Partners with Apellis for Gene Therapy Development in AMD

Fineline Cube Dec 26, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with US firm...

Company Drug

Jing Medicine’s HJM-353 Gains Clinical Trial Approvals in US and China

Fineline Cube Dec 26, 2022

China-based Jing Medicine Technology (Shanghai) Co., Ltd’s HJM-353 has obtained clinical trial approvals in the...

Company Deals

Jiangsu Vcare PharmaTech Raises RMB 200 Million in Series B Financing Round

Fineline Cube Dec 26, 2022

China-based Jiangsu Vcare PharmaTech Co. Ltd has reportedly raised over RMB 200 million (USD 28.67...

Company Drug

MindRank AI Receives FDA Approval for MDR-001 Clinical Study in Obesity

Fineline Cube Dec 26, 2022

Hangzhou-based artificial intelligence (AI)-driven biotech MindRank AI has announced obtaining approval from the US FDA...

Company Medical Device

Hangzhou Biotest Receives FDA EUA for COVID-19 Antigen Self-Testing Reagent

Fineline Cube Dec 26, 2022

China-based Hangzhou Biotest Biotech Co., Ltd has announced receiving an Emergency Use Authorization (EUA) from...

Company Deals

Junshi Biosciences Licenses PD-1 Inhibitor Tuoyi to Hikma MENA FZE

Fineline Cube Dec 26, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a licensing agreement with UK-headquartered Hikma...

Company Deals

Shanghai Pharmaceuticals Secures Exclusive Rights for Shionogi’s Ensitrelvir in China

Fineline Cube Dec 26, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced an import and distribution agreement with Japan-based...

Company Drug

WHO Approves Sinovac’s CoronaVac for Children Aged 3 and Above

Fineline Cube Dec 23, 2022

The World Health Organization (WHO) has lowered the age limit for Sinovac Biotech Ltd’s (NASDAQ:...

Policy / Regulatory

NHSA Orders Investigation into Unreasonable Medical Insurance Restrictions

Fineline Cube Dec 23, 2022

The National Healthcare Security Administration (NHSA) has released a notification to medical insurance departments across...

Company Drug

Fosun Pharma’s Avatrombopag Receives NMPA Review for Chronic ITP Indication

Fineline Cube Dec 23, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that another...

Company Deals

Nanjing Pharmaceutical to Acquire Majority Stakes in Three Jiangsu Subsidiaries

Fineline Cube Dec 23, 2022

China-based Shanghai-listed Nanjing Pharmaceutical Co., Ltd (SHA: 600713) is set to acquire a respective 55%,...

Company Deals

MSD and Kelun Biotech Ink Record-Breaking ADC Deal

Fineline Cube Dec 23, 2022

Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest...

Policy / Regulatory

NMPA and GAC Release Notification on Import and Export Management of Narcotic Drugs

Fineline Cube Dec 23, 2022

The National Medical Products Administration (NMPA) and the General Administration of Customs (GAC) have released...

Company Drug

Shyndec’s Generic Cytosar-U Gains Marketing Approval in China

Fineline Cube Dec 23, 2022

China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of...

Company Medical Device

Sino Medical Sciences’ NC Rockstar Catheter Approved by US FDA

Fineline Cube Dec 23, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving market approval from the...

Company Drug

Antengene Files for Xpovio Approval in Macau, Malaysia, and Thailand

Fineline Cube Dec 23, 2022

Antengene Corp., Ltd (HKG: 6996) has announced market filings for its Xpovio (selinexor) in Macau,...

Drug

Eisai and Biogen Initiate BLA in China for Alzheimer’s Therapy Lecanemab

Fineline Cube Dec 23, 2022

Japan-based Eisai Co., Ltd (TYO: 4523) and its US co-development partner Biogen Inc. (NASDAQ: BIIB)...

Company Deals

Qitan Tech Raises RMB 700 Million in Series C Financing Led by Meituan

Fineline Cube Dec 23, 2022

Qitan Tech, a nanopore gene sequencer maker based in Chengdu, has reportedly raised RMB 700...

Company Drug

Kanghong’s Escitalopram Oral Solution Receives NMPA Marketing Approval

Fineline Cube Dec 23, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving marketing approval from...

Posts pagination

1 … 527 528 529 … 610

Recent updates

  • Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
  • Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
  • Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic
  • Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
  • Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.